Astellas at TPD Summit 2026

Oct 26–29, 2026 Boston, MA ~300 attendees Website

Astellas takes part in 2 sessions at TPD Summit 2026 in Boston. Its program covers both ends of degrader development, with clinical proof of concept for setidegrasib (ASP3082) and an update on optimizing new heterobifunctional degraders.

OrganizationTPD Summit 2026 Attendance
Astellas
Tokyo, Japan
◇Industry Partner
astellas.com
Large pharmaIndustry Partner
Japanese pharmaceutical company with a targeted protein degradation program, including the KRAS G12D degrader setidegrasib.
Talk
Tue Oct 27
2:00pm
Clinical Proof of Concept of Setidegrasib (ASP3082)
Track C: Translational & Clinical Development
Talk
Wed Oct 28
3:00pm
Optimizing Novel Heterobifunctional Degraders – An Update
Track A: Discovery

Explore the full TPD Summit 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full TPD Summit 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Astellas

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction